MGC Pharmaceuticals Ltd
ASX:MXC

Watchlist Manager
MGC Pharmaceuticals Ltd Logo
MGC Pharmaceuticals Ltd
ASX:MXC
Watchlist
Price: 0.415 AUD Market Closed
Market Cap: 18.2m AUD

MGC Pharmaceuticals Ltd
Investor Relations

MGC Pharmaceuticals Ltd. engages in the production of medical marijuana. The company is headquartered in Perth, Western Australia. The company went IPO on 2006-12-21. The firm is primarily focused on producing standardized, phytocannabinoid and plant-derived medicines. The Company’s Nature to Medicine strategy comprises the entire supply chain, from botanical research, to develop new strains of Cannabis Sativa, preclinical and clinical research, product manufacturing, distribution, as well as the development of drug delivery systems. The Group has also completed a Phase II double-blind, randomized, placebo controlled clinical trial in Israel and India, to evaluate the safety and efficacy of a natural anti-inflammatory based formulation ArtemiC on patients diagnosed with Corona Virus Disease 2019 (COVID-19).

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
No Earnings Calls Available

Management

Contacts

Address
WESTERN AUSTRALIA
Perth
1202 Hay St,
Contacts
+61863823390.0
mgcpharma.com.au